BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469. [PMID: 16890600 DOI: 10.1053/j.gastro.2006.05.021] [Cited by in Crossref: 524] [Cited by in F6Publishing: 460] [Article Influence: 34.9] [Reference Citation Analysis]
Number Citing Articles
1 Hayashi A, Yamauchi N, Shibahara J, Kimura H, Morikawa T, Ishikawa S, Nagae G, Nishi A, Sakamoto Y, Kokudo N, Aburatani H, Fukayama M. Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One 2014;9:e91330. [PMID: 24614346 DOI: 10.1371/journal.pone.0091330] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
2 Li XL, Guo WX, Hong XD, Yang L, Wang K, Shi J, Li N, Wu MC, Cheng SQ. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. Hepatol Res. 2016;46:1088-1098. [PMID: 26783741 DOI: 10.1111/hepr.12657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
3 Moon H, Choi JE, Lee IJ, Kim TH, Kim SH, Ko YH, Kim HB, Nam BH, Park JW. All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. J Cancer Res Clin Oncol 2017;143:2327-39. [PMID: 28744575 DOI: 10.1007/s00432-017-2480-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Gwon D, Ko G, Yoon H, Sung K, Kim JH, Lee SS, Lee JM, Ohm J, Shin JH, Song H. Hepatocellular Carcinoma Associated with Membranous Obstruction of the Inferior Vena Cava: Incidence, Characteristics, and Risk Factors and Clinical Efficacy of TACE. Radiology 2010;254:617-26. [DOI: 10.1148/radiol.09090738] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
5 Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) 2015;17:1137-44. [PMID: 26374137 DOI: 10.1111/hpb.12487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sueyoshi E, Hayashida T, Sakamoto I, Uetani M. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2010;195:245-51. [PMID: 20566824 DOI: 10.2214/AJR.08.2301] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
7 Suzuki E, Chiba T, Ooka Y, Ogasawara S, Tawada A, Motoyama T, Kanogawa N, Saito T, Yoshikawa M, Yokosuka O. Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates? World J Gastroenterol 2015;21:8888-93. [PMID: 26269678 DOI: 10.3748/wjg.v21.i29.8888] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol. 2007;14:2817-2823. [PMID: 17690940 DOI: 10.1245/s10434-007-9518-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 6.1] [Reference Citation Analysis]
9 Yang B, Li CL, Guo WH, Qin TQ, Jiao H, Fei ZJ, Zhou X, Duan LJ, Liao ZY. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer 2018;18:101. [PMID: 29378532 DOI: 10.1186/s12885-018-3989-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
11 Hiraoka A, Otsuka Y, Kawasaki H, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Mori I, Hiasa Y, Michitaka K. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2018;33:1271-6. [PMID: 29193248 DOI: 10.1111/jgh.14058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. American Journal of Roentgenology 2016;206:645-54. [DOI: 10.2214/ajr.15.14758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
13 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 45] [Article Influence: 12.9] [Reference Citation Analysis]
14 Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Aoyagi Y. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med 2013;2:86-98. [PMID: 24133631 DOI: 10.1002/cam4.55] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
15 Cai ZQ, Si SB, Chen C, Zhao Y, Ma YY, Wang L, Geng ZM. Analysis of prognostic factors for survival after hepatectomy for hepatocellular carcinoma based on a Bayesian network. PLoS One. 2015;10:e0120805. [PMID: 25826337 DOI: 10.1371/journal.pone.0120805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
16 Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer 2016;5:190-7. [PMID: 27493894 DOI: 10.1159/000367775] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
17 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol. 2010;16:264-269. [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
18 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 90.0] [Reference Citation Analysis]
19 Gjoreski A, Jovanoska I, Risteski F, Prgova Veljanova B, Nedelkovski D, Dimov V, Popova Jovanovska R, Grozdanovska Angelovska B, Mitrevski N, Dimova B. Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. Eur J Cancer Prev 2021;30:258-66. [PMID: 33038087 DOI: 10.1097/CEJ.0000000000000623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
21 Hu H, Duan Z, Long X, Hertzanu Y, Tong X, Xu X, Shi H, Liu S, Yang Z. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. PLoS One 2015;10:e0117168. [PMID: 25689846 DOI: 10.1371/journal.pone.0117168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, Gruber-Rouh T. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer. 2012;131:733-740. [PMID: 21976289 DOI: 10.1002/ijc.26407] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 7.8] [Reference Citation Analysis]
23 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 96] [Article Influence: 12.0] [Reference Citation Analysis]
24 Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer 2016;5:175-89. [PMID: 27493893 DOI: 10.1159/000367765] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
25 Xu H, Yu X, Hu J. The Risk Assessment and Clinical Research of Bile Duct Injury After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:5039-52. [PMID: 34234549 DOI: 10.2147/CMAR.S303172] [Reference Citation Analysis]
26 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6:325-336. [PMID: 29234636 DOI: 10.1159/000479984] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
27 Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis. 2013;14:181-190. [PMID: 23324079 DOI: 10.1111/1751-2980.12038] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.8] [Reference Citation Analysis]
28 Park W, Chung YH, Kim JA, Jin YJ, Lee D, Shim JH, Lee D, Kim KM, Lim YS, Lee HC. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. Hepatol Res. 2013;43:1304-1312. [PMID: 23442052 DOI: 10.1111/hepr.12083] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
29 Nishikawa H, Osaki Y. Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2014;44:149-158. [PMID: 23819582 DOI: 10.1111/hepr.12194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
30 Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl. 2011;17 Suppl 2:S26-S33. [PMID: 21656653 DOI: 10.1002/lt.22352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
31 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Control 2010;17:87-99. [PMID: 20404792 DOI: 10.1177/107327481001700204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
32 Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;78:188-93. [PMID: 20133077 DOI: 10.1016/j.ijrobp.2009.07.1725] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
33 Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process. Journal of Hepatology 2015;62:855-62. [DOI: 10.1016/j.jhep.2014.11.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 13.5] [Reference Citation Analysis]
34 Barzakova ES, Schulze-Hagen M, Zimmermann M, Lurje G, Bednarsch J, Pedersoli F, Isfort P, Kuhl C, Bruners P. Monitoring Liver Function of Patients Undergoing Transarterial Chemoembolization (TACE) by a 13C Breath Test (LiMAx). Cardiovasc Intervent Radiol 2019;42:1702-8. [PMID: 31535181 DOI: 10.1007/s00270-019-02325-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Kasai K, Ushio A, Sawara K, Miyamoto Y, Kasai Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2010;16:3437-3444. [PMID: 20632449 DOI: 10.3748/wjg.v16.i27.3437] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kang BK, Kim JH, Kim KM, Ko GY, Yoon HK, Gwon DI, Sung KB. Transcatheter arterial chemoembolization for hepatocellular carcinoma after attempted portal vein embolization in 25 patients. AJR Am J Roentgenol. 2009;193:W446-W451. [PMID: 19843726 DOI: 10.2214/AJR.09.2479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
37 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
38 Younes EH, Zahra HF, Soumaya BM, Maria L, Nada L, Hakima A, Samira EF, Meriem H, Badreddine A, Youssef H, Imane K, Meryem B, Noureddine A, Adil IS, Mustapha M, Youssef ALM. Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients. Clin Exp Hepatol 2020;6:313-20. [PMID: 33511278 DOI: 10.5114/ceh.2020.102169] [Reference Citation Analysis]
39 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
40 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
41 Wang J, Changchien C, Hu T, Lee C, Kee K, Lin C, Chen C, Chen T, Huang Y, Lu S. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 patients. European Journal of Cancer 2008;44:1000-6. [DOI: 10.1016/j.ejca.2008.02.018] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 10.9] [Reference Citation Analysis]
42 Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res 2019;49:919-28. [PMID: 30969006 DOI: 10.1111/hepr.13348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
43 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Boulin M, Adam H, Guiu B, Aho LS, Cercueil JP, Di Martino C, Fagnoni P, Minello A, Jouve JL, Hillon P, Bedenne L, Lepage C. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Dig Liver Dis. 2014;46:358-362. [PMID: 24462550 DOI: 10.1016/j.dld.2013.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
45 Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM. Gadoxetate Disodium–Enhanced Hepatic MRI: Dose-Dependent Contrast Dynamics of Hepatic Parenchyma and Portal Vein. American Journal of Roentgenology 2011;196:W18-24. [DOI: 10.2214/ajr.10.4387] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Hiraoka A, Nagamatsu K, Izumoto H, Adachi T, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K. Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. Hepatol Res 2020;50:92-100. [PMID: 31729124 DOI: 10.1111/hepr.13430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
47 Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462-467. [PMID: 18243571 DOI: 10.1016/j.ijrobp.2007.09.056] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
48 Eguchi S, Matsumoto S, Hamasaki K, Takatsuki M, Hidaka M, Tajima Y, Sakamoto I, Kanematsu T. Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection. J Hepatobiliary Pancreat Surg. 2008;15:627-633. [PMID: 18987934 DOI: 10.1007/s00534-007-1341-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
49 Zhao H, Zhai X, Chen Z, Wan X, Chen L, Shen F, Ling C. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. Oncotarget 2017;8:45234-41. [PMID: 28423370 DOI: 10.18632/oncotarget.16804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011;80:188-194. [PMID: 21709428 DOI: 10.1159/000328749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
51 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 223] [Article Influence: 21.1] [Reference Citation Analysis]
52 Shimohira M, Ogino H, Kawai T, Kushita A, Watanabe M, Kawaguchi T, Kurono K, Shibamoto Y. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. Br J Radiol 2011;84:184-7. [PMID: 21257838 DOI: 10.1259/bjr/26974088] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
53 Dabbous HK, Ali-Eldin FA, Montasser IM. Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients. Arab J Gastroenterol 2015;16:10-3. [PMID: 25865041 DOI: 10.1016/j.ajg.2015.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
55 Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol 2013;13:105. [PMID: 23800233 DOI: 10.1186/1471-230X-13-105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
56 Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011;5:850-856. [PMID: 21484134 DOI: 10.1007/s12072-010-9249-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
57 Zheng N, Wei X, Zhang D, Chai W, Che M, Wang J, Du B. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore). 2016;95:e3959. [PMID: 27367992 DOI: 10.1097/md.0000000000003959] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
58 Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021;73:1381-98. [PMID: 32609900 DOI: 10.1002/hep.31448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
59 Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, Park JY, Kim do Y, Ahn SH, Kim MD. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304-1310. [PMID: 25637785 DOI: 10.1016/j.jhep.2015.01.022] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 13.8] [Reference Citation Analysis]
60 Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26:320-9.e6. [PMID: 25612807 DOI: 10.1016/j.jvir.2014.10.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
61 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
62 Sun JH, Zhou T, Zhu T, Zhang Y, Nie C, Ai J, Zhou G, Zhang A, Dong MJ, Wang WL, Zheng SS. Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. Biomed Res Int. 2016;2016:3048261. [PMID: 27999793 DOI: 10.1155/2016/3048261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
63 Yao X, Yan D, Jiang X, Li X, Zeng H, Liu D, Li H. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer. Acad Radiol. 2018;25:1031-1037. [PMID: 29398432 DOI: 10.1016/j.acra.2017.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
64 Tacher V, Duran R, Lin M, Sohn JH, Sharma KV, Wang Z, Chapiro J, Gacchina Johnson C, Bhagat N, Dreher MR, Schäfer D, Woods DL, Lewis AL, Tang Y, Grass M, Wood BJ, Geschwind JF. Multimodality Imaging of Ethiodized Oil-loaded Radiopaque Microspheres during Transarterial Embolization of Rabbits with VX2 Liver Tumors. Radiology 2016;279:741-53. [PMID: 26678453 DOI: 10.1148/radiol.2015141624] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
65 Abdalla EK, Denys A, Hasegawa K, Leung TW, Makuuchi M, Murthy R, Ribero D, Zorzi D, Vauthey JN, Torzilli G. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol. 2008;15:979-985. [PMID: 18236115 DOI: 10.1245/s10434-007-9727-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
66 Teh SH, Sheppard BC, Schwartz J, Orloff SL. Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Am J Surg. 2008;195:697-701. [PMID: 18367132 DOI: 10.1016/j.amjsurg.2007.05.054] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
67 Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29:558-568. [PMID: 23937321 DOI: 10.3109/02656736.2013.821528] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
68 Hu Z, Zhou J, Xu X, Li Z, Zhou L, Wu J, Zhang M, Zheng S. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One. 2012;7:e36587. [PMID: 22574187 DOI: 10.1371/journal.pone.0036587] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
69 Peng J, Kang S, Ning Z, Deng H, Shen J, Xu Y, Zhang J, Zhao W, Li X, Gong W, Huang J, Liu L. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. Eur Radiol. 2020;30:413-424. [PMID: 31332558 DOI: 10.1007/s00330-019-06318-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 14.5] [Reference Citation Analysis]
70 Zhao M, Wang JP, Pan CC, Li W, Huang ZL, Zhang L, Fang WJ, Jiang Y, Li XS, Wu PH. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81:2717-25. [PMID: 22245655 DOI: 10.1016/j.ejrad.2011.10.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
71 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
72 Hartrumpf KJ, Marquardt S, Werncke T, Murray T, Kirstein MM, Vogel A, Wacker F, Rodt T. Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. J Cancer Res Clin Oncol 2018;144:1991-9. [PMID: 30008024 DOI: 10.1007/s00432-018-2704-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
73 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Osuga K, Maeda N, Higashihara H, Hori S, Nakazawa T, Tanaka K, Nakamura M, Kishimoto K, Ono Y, Tomiyama N. Current status of embolic agents for liver tumor embolization. Int J Clin Oncol 2012;17:306-15. [PMID: 22806426 DOI: 10.1007/s10147-012-0445-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
75 Wei H, Huang J, Yang J, Zhang X, Lin L, Xue E, Chen Z. Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts. PLoS One. 2013;8:e58133. [PMID: 23469265 DOI: 10.1371/journal.pone.0058133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
76 Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-77; quiz 578. [PMID: 22158026 DOI: 10.1038/ajg.2011.425] [Cited by in Crossref: 406] [Cited by in F6Publishing: 357] [Article Influence: 40.6] [Reference Citation Analysis]
77 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 158] [Article Influence: 28.2] [Reference Citation Analysis]
78 Wang JH, Wei W, Guo ZX, Shi M, Guo RP. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. J Transl Med 2015;13:41. [PMID: 25638165 DOI: 10.1186/s12967-015-0396-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
79 Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, Shiraki K, Yamada T, Takeda K. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009;20:217-224. [PMID: 19097810 DOI: 10.1016/j.jvir.2008.10.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
80 Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 2014;9:e96620. [PMID: 24817002 DOI: 10.1371/journal.pone.0096620] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
81 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
82 Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81:1039-1045. [PMID: 20888707 DOI: 10.1016/j.ijrobp.2010.07.015] [Cited by in Crossref: 102] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
83 Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, Torimura T. Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett 2020;19:2667-76. [PMID: 32218817 DOI: 10.3892/ol.2020.11399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Liu QY, He CD, Zhou Y, Huang D, Lin H, Wang Z, Wang D, Wang JQ, Liao LP. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol 2016;22:3242-51. [PMID: 27004002 DOI: 10.3748/wjg.v22.i11.3242] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan: 18th follow-up survey of primary liver cancer. Hepatology Research 2010;40:1043-59. [DOI: 10.1111/j.1872-034x.2010.00731.x] [Cited by in Crossref: 89] [Article Influence: 8.1] [Reference Citation Analysis]
86 Wang JH, Wei W, Xu J, Guo ZX, Xiao CZ, Zhang YF, Jian PE, Wu XL, Shi M, Guo RP. Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget 2015;6:35116-28. [PMID: 26375669 DOI: 10.18632/oncotarget.5057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
87 Su TS, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, Chen L, Xiang BD, Zhao C, Huang DJ, Liang SX, Li LQ. Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front Oncol 2020;10:347. [PMID: 32266136 DOI: 10.3389/fonc.2020.00347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
88 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
90 Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013;43:942-949. [PMID: 23301851 DOI: 10.1111/hepr.12041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
91 Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012;4:405-412. [PMID: 23024842 DOI: 10.4329/wjr.v4.i9.405] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
92 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164-2174. [PMID: 19739081 DOI: 10.1002/ijc.24882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
93 Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, Hariprasad S, Ranjan P, Arora A, Gupta A. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India. Indian J Gastroenterol 2015;34:117-26. [PMID: 25937484 DOI: 10.1007/s12664-015-0544-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
94 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 12.2] [Reference Citation Analysis]
95 Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426-432. [PMID: 23269991 DOI: 10.1200/jco.2012.42.9936] [Cited by in Crossref: 260] [Cited by in F6Publishing: 120] [Article Influence: 28.9] [Reference Citation Analysis]
96 Han K, Kim JH, Yoon HM, Kim EJ, Gwon DI, Ko GY, Yoon HK, Ko HK. Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival. Korean J Radiol. 2014;15:464-471. [PMID: 25053906 DOI: 10.3348/kjr.2014.15.4.464] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
97 Eguchi S, Hidaka M, Tomonaga T, Miyazaki K, Inokuma T, Takatsuki M, Okudaira S, Yamanouchi K, Miyaaki H, Ichikawa T, Tajima Y, Kanematsu T. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624-9. [PMID: 19381752 DOI: 10.1007/s00535-009-0043-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
98 Irie T, Takahashi N, Kamoshida T, Kashimura J, Ariga H. Balloon-Occluded Trans-Arterial Chemo-Embolization Technique with Repeated Alternate Infusion of Cisplatin Solution and Sparse Gelatin Slurry (RAIB-TACE) for Large Hepatocellular Carcinoma Nodules More than 7 cm in Diameter. Biomed Res Int 2020;2020:9289321. [PMID: 32051830 DOI: 10.1155/2020/9289321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
99 Kulik LM. Advancements in hepatocellular carcinoma: . Current Opinion in Gastroenterology 2007;23:268-74. [DOI: 10.1097/mog.0b013e3280ec5113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
100 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
101 Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C. Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018;14:1165-1176. [PMID: 29334777 DOI: 10.2217/fon-2017-0354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
102 Yamane B, Weber S. Liver-Directed Treatment Modalities for Primary and Secondary Hepatic Tumors. Surgical Clinics of North America 2009;89:97-113. [DOI: 10.1016/j.suc.2008.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
103 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 249] [Article Influence: 30.3] [Reference Citation Analysis]
104 Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013;24:1639-1646. [PMID: 23962438 DOI: 10.1016/j.jvir.2013.06.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
105 Nishikawa H, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: Clinical outcome and safety in elderly patients. J Cancer. 2014;5:590-597. [PMID: 25057310 DOI: 10.7150/jca.9413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
106 Iezzi R, Cesario V, Siciliani L, Campanale M, De Gaetano AM, Siciliano M, Agnes S, Giuliante F, Grieco A, Pompili M, Rapaccini GL, Gasbarrini A, Bonomo L, HepatoCATT Group for the Multidisciplinary Management of HCC. Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE). Radiol Med. 2013;118:555-569. [PMID: 23358819 DOI: 10.1007/s11547-012-0914-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
107 Jazieh KA, Arabi M, Khankan AA. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol 2014;20:333-41. [PMID: 25434313 DOI: 10.4103/1319-3767.145315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Wang Z, Qu K, Huang Z, Xu X, Zhang J, Zhang L, Liu S, Chang H, Lin T, Liu Y, Niu W, Liu C. Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma. Tumor Biol 2015;36:6463-9. [DOI: 10.1007/s13277-015-3336-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
109 Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:e189-e197. [PMID: 18466288 DOI: 10.1111/j.1440-1746.2008.05340.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
110 Hiraki T, Koizumi J, Arai Y, Sakurai Y, Kumada H, Nambu Y, Hori S. Transcatheter arterial embolization of hypervascular tumors with HepaSphere: prospective multicenter open label clinical trial of microspheres in Japan. Jpn J Radiol 2015;33:479-86. [DOI: 10.1007/s11604-015-0448-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
112 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Shimada K, Sakamoto Y, Esaki M, Kosuge T. Role of a hepatectomy for the treatment of large hepatocellular carcinomas measuring 10 cm or larger in diameter. Langenbecks Arch Surg 2008;393:521-6. [DOI: 10.1007/s00423-007-0264-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
114 Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 2018;53:281-90. [PMID: 28766016 DOI: 10.1007/s00535-017-1374-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
115 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
116 Shi Y, Xu T, Li L, Chen X. Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol. J Huazhong Univ Sci Technol [Med Sci ] 2013;33:90-5. [DOI: 10.1007/s11596-013-1077-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
117 Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther 2016;10:2461-6. [PMID: 27536066 DOI: 10.2147/DDDT.S113295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
118 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
119 Maeda N, Osuga K, Mikami K, Higashihara H, Onishi H, Nakaya Y, Tatsumi M, Hori M, Kim T, Tomoda K, Nakamura H. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 2008;26:206-12. [DOI: 10.1007/s11604-007-0216-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
120 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
121 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
122 Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22:1697-1705. [PMID: 21983055 DOI: 10.1016/j.jvir.2011.08.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
123 Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, Motoyama H, Furusawa N, Notake T, Kitagawa N. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol. 2014;19:871-879. [PMID: 24218280 DOI: 10.1007/s10147-013-0634-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
124 Matsui O, Miyayama S, Sanada J, Kobayashi S, Khoda W, Minami T, Kozaka K, Gabata T. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci. 2010;17:407-409. [PMID: 19885639 DOI: 10.1007/s00534-009-0234-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
125 Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Thono E, Tsuboi K, Tokuuye K. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831-836. [PMID: 19304408 DOI: 10.1016/j.ijrobp.2008.10.073] [Cited by in Crossref: 147] [Cited by in F6Publishing: 107] [Article Influence: 12.3] [Reference Citation Analysis]
126 Nicolini A, Crespi S, Martinetti L. Drug delivery embolization systems: a physician's perspective. Expert Opin Drug Deliv 2011;8:1071-84. [PMID: 21692688 DOI: 10.1517/17425247.2011.590472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
127 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
128 Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, Kim BH, Lee JH, Kang HY, Shin HD, Song IH. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol 2012;18:48-55. [PMID: 22511903 DOI: 10.3350/kjhep.2012.18.1.48] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
129 You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, Choi IB, Lee DH, Chun HJ, Choi BG. Efficacy of Transarterial Chemolipiodolization with or without 3-Dimensional Conformal Radiotherapy for Huge HCC with Portal Vein Tumor Thrombosis. Korean J Hepatol 2007;13:378. [DOI: 10.3350/kjhep.2007.13.3.378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
130 Kim YJ, Lee MH, Choi SY, Yi BH, Lee HK. Magnetic resonance imaging features predictive of an incomplete response to transarterial chemoembolization in patients with hepatocellular carcinoma: A STROBE-compliant study. Medicine (Baltimore) 2019;98:e15592. [PMID: 31083245 DOI: 10.1097/MD.0000000000015592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatol Res 2018;48:E61-7. [PMID: 28628718 DOI: 10.1111/hepr.12927] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
132 Yang M, Zhong X, Yuan Y. Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review. Integr Cancer Ther 2020;19:1534735420922579. [PMID: 32448009 DOI: 10.1177/1534735420922579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
133 Siriwardana RC, Niriella MA, Dassanayake AS, Liyanage CA, Upasena A, Sirigampala C, de Silva HJ. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. BMC Gastroenterol 2015;15:96. [PMID: 26239844 DOI: 10.1186/s12876-015-0329-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
134 Mendizabal M, Reddy KR. Current Management of Hepatocellular Carcinoma. Medical Clinics of North America 2009;93:885-900. [DOI: 10.1016/j.mcna.2009.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
135 Hiraoka A, Ichiryu M, Tazuya N, Ochi H, Tanabe A, Nakahara H, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett 2010;1:57-61. [PMID: 22966256 DOI: 10.3892/ol_00000010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
136 Radeleff B, Stampfl U, Sommer C, Bellemann N, Hoffmann K, Ganten T, Ehehalt R, Kauczor H. Transvaskuläre Ablation des hepatozellulären Karzinoms: Ist Chemotherapie alles? Radiologe 2012;52:44-55. [DOI: 10.1007/s00117-011-2211-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
138 Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, Yutani S, Harada K, Sata M. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res. 2014;44:194-200. [PMID: 23521520 DOI: 10.1111/hepr.12100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
139 Othman MH, Mourad AF, Abd Ellah MM, Imam HM. Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma. The Egyptian Journal of Radiology and Nuclear Medicine 2014;45:395-401. [DOI: 10.1016/j.ejrnm.2014.02.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
141 Li Z, Jiao D, Si G, Han X, Zhang W, Li Y, Zhou X, Liu J, Li J, Liu Z. Making timely remedial measures after TACE based on the results of cone-beam CT liver perfusion. Int J Hyperthermia 2021;38:428-36. [PMID: 33691589 DOI: 10.1080/02656736.2021.1895331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
142 Liu W, Xu H, Ying X, Zhang D, Lai L, Wang L, Tu J, Ji J. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome. Med Sci Monit 2020;26:e923263. [PMID: 32667906 DOI: 10.12659/MSM.923263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
143 Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology. 2010;51:1264-1273. [PMID: 20099300 DOI: 10.1002/hep.23456] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 8.1] [Reference Citation Analysis]
144 Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82-88. [PMID: 24650695 DOI: 10.1016/j.jhep.2014.03.012] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 20.7] [Reference Citation Analysis]
145 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
146 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
147 Gade TPF, Tucker E, Nakazawa MS, Hunt SJ, Wong W, Krock B, Weber CN, Nadolski GJ, Clark TWI, Soulen MC, Furth EE, Winkler JD, Amaravadi RK, Simon MC. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 2017;283:702-10. [PMID: 28253108 DOI: 10.1148/radiol.2017160728] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
148 Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:530-536. [PMID: 23216217 DOI: 10.1111/jgh.12087] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
149 Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014;3:415-8. [PMID: 25568865 DOI: 10.3978/j.issn.2304-3881.2014.07.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
150 Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer. 2014;3:53-61. [PMID: 24804177 DOI: 10.1159/000343858] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
151 Satake M, Uchida H, Arai Y, Anai H, Sakaguchi H, Nagata T, Yamane T, Kichikawa K, Osaki Y, Okazaki M, Higashihara H, Nakamura H, Osuga K, Nakao N, Hirota S. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008;31:756-61. [PMID: 18389187 DOI: 10.1007/s00270-007-9255-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
152 Matsui O. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clin Drug Investig 2012;32 Suppl 2:3-13. [PMID: 22873623 DOI: 10.1007/BF03265492] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
153 Miyayama S, Yamashiro M, Nagai K, Tohyama J, Kawamura K, Yoshida M, Sakuragawa N. Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging: CT vs Gd-EOB-MRI for recurrent HCC after cTACE. Hepatol Res 2016;46:890-8. [DOI: 10.1111/hepr.12632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
154 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013;48:951-65. [PMID: 23065022 DOI: 10.1007/s00535-012-0690-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
155 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:247-259. [PMID: 22941025 DOI: 10.1007/978-3-642-16037-0_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
157 Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, Zhong Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014;35:7407-7413. [PMID: 24777334 DOI: 10.1007/s13277-014-1976-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
158 Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509-517. [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
159 Kim HJ, Shin JH, Kim T, Kim EY, Park YS, Park C, Song H. Efficacy of Transarterial Embolization with Arsenic Trioxide Oil Emulsion in a Rabbit VX2 Liver Tumor Model. Journal of Vascular and Interventional Radiology 2009;20:1365-70. [DOI: 10.1016/j.jvir.2009.07.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
160 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
161 Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci 2013;20:332-41. [PMID: 22710886 DOI: 10.1007/s00534-012-0527-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
162 Nagai H, Matsui T, Kanayama M, Wakui N, Momiyama K, Watanabe M, Igarashi Y, Sumino Y. Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011;68:139-45. [PMID: 20857114 DOI: 10.1007/s00280-010-1465-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
163 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52-64. [DOI: 10.1053/j.gastro.2009.09.006] [Cited by in Crossref: 650] [Cited by in F6Publishing: 521] [Article Influence: 59.1] [Reference Citation Analysis]
164 Ikoma A, Kawai N, Sato M, Minamiguchi H, Nakai M, Nakata K, Tanaka T, Sonomura T. Comparison of blood dynamics of anticancer drugs (cisplatin, mitomycin C, epirubicin) in treatment groups of hepatic arterial infusion, hepatic arterial infusion with lipiodol and transcatheter arterial chemoembolization with lipiodol plus gelatin sponge particles in a swine model. Hepatol Res 2012;42:1227-35. [PMID: 22607607 DOI: 10.1111/j.1872-034X.2012.01040.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
165 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
166 Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35:1119-1128. [PMID: 22614031 DOI: 10.1007/s00270-012-0394-0] [Cited by in Crossref: 119] [Cited by in F6Publishing: 99] [Article Influence: 13.2] [Reference Citation Analysis]
167 Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, Santis AD, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology 2018;17:110-8. [DOI: 10.5604/01.3001.0010.7542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
168 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
169 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol 2014;35:8355-8. [PMID: 25195949 DOI: 10.1007/s13277-014-2571-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
171 Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, Gu JP, Wang Q. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. [PMID: 32157110 DOI: 10.1038/s41598-020-61209-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
172 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
173 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
174 Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173-1178. [PMID: 21466931 DOI: 10.1016/j.ejrad.2011.03.046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
175 Jin C, Zhu H, Wang Z, Wu F, Chen W, Li K, Su H, Zhou K, Gong W. High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis. Eur J Radiol. 2011;80:662-669. [PMID: 20864286 DOI: 10.1016/j.ejrad.2010.08.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
176 Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol. 2008;23:482-490. [PMID: 18086115 DOI: 10.1111/j.1440-1746.2007.05262.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
177 Kohla MA, Abu Zeid MI, Al-Warraky M, Taha H, Gish RG. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol 2015;2:e000032. [PMID: 26462282 DOI: 10.1136/bmjgast-2015-000032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
178 Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010;25:1299-305. [PMID: 20594260 DOI: 10.1111/j.1440-1746.2010.06267.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
179 Osuga K, Hori S, Hiraishi K, Sugiura T, Hata Y, Higashihara H, Maeda N, Tomoda K, Nakamura H. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol. 2008;31:1108-1116. [PMID: 18543028 DOI: 10.1007/s00270-008-9369-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
180 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014;20:16630-8. [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
181 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
182 Loffroy R, Lin M, Rao P, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Geschwind J. Comparing the Detectability of Hepatocellular Carcinoma by C-Arm Dual-Phase Cone-Beam Computed Tomography During Hepatic Arteriography With Conventional Contrast-Enhanced Magnetic Resonance Imaging. Cardiovasc Intervent Radiol 2012;35:97-104. [DOI: 10.1007/s00270-011-0118-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
183 Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int 2018;38:1646-54. [PMID: 29436101 DOI: 10.1111/liv.13719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
184 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
185 Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291-1298. [PMID: 19392861 DOI: 10.1111/j.1365-2036.2009.04016.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
186 Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65. [PMID: 17953709 DOI: 10.1111/j.1349-7006.2007.00648.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 71] [Article Influence: 0.9] [Reference Citation Analysis]
187 Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R, Jakobs T, Helmberger T. Update Chemoperfusion und -embolisation. Radiologe 2007;47:1097-108. [DOI: 10.1007/s00117-007-1587-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
188 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 14.8] [Reference Citation Analysis]
189 Shi Z, Yang W, Tang H, Li X. Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25851. [PMID: 34011050 DOI: 10.1097/MD.0000000000025851] [Reference Citation Analysis]
190 Choi JW, Park JY, Ahn SH, Yoon KT, Ko HK, Lee DY, Lee JT, Kim KS, Choi JS, Han KH. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am J Clin Oncol. 2009;32:564-569. [PMID: 19564783 DOI: 10.1097/COC.0b013e3181967da0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
191 Ali S, Ejaz M, Dar KK, Nasreen S, Ashraf N, Gillani SF, Shafi N, Safeer S, Khan MA, Andleeb S, Akhtar N, Mughal TA. Evaluation of chemopreventive and chemotherapeutic effect of Artemisia vulgaris extract against diethylnitrosamine induced hepatocellular carcinogenesis in Balb C mice. Braz J Biol 2020;80:484-96. [DOI: 10.1590/1519-6984.185979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
192 Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F. Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. Gut Liver. 2013;7:246-251. [PMID: 23560163 DOI: 10.5009/gnl.2013.7.2.246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Ren Y, Dong X, Chen L, Sun T, Alwalid O, Kan X, Su Y, Xiong B, Liang H, Zheng C, Han P. Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization. Front Oncol 2021;11:582544. [PMID: 33738247 DOI: 10.3389/fonc.2021.582544] [Reference Citation Analysis]
194 Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Stein LL, Panjala C, Tan M, Arepally A. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:647-654. [PMID: 23384831 DOI: 10.1016/j.jvir.2012.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
195 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
196 Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12-S20. [PMID: 17449346 DOI: 10.1053/j.seminoncol.2007.01.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
197 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
198 Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg. 2009;13:1921-1928. [PMID: 19727969 DOI: 10.1007/s11605-009-0998-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
199 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Rep (Hoboken) 2021;:e1464. [PMID: 34114752 DOI: 10.1002/cnr2.1464] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Norén A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB (Oxford) 2010;12:637-43. [PMID: 20961372 DOI: 10.1111/j.1477-2574.2010.00210.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
201 Yoon H, Kim J, Kim K, Lee I, Ko G, Song H, Gwon D. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clinical Radiology 2010;65:271-7. [DOI: 10.1016/j.crad.2010.01.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
202 Kim JH, Yoon H, Ko G, Gwon DI, Jang CS, Song H, Shin JH, Sung K. Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization. Radiology 2010;255:270-7. [DOI: 10.1148/radiol.09091076] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
203 Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118:4725-4736. [PMID: 22359112 DOI: 10.1002/cncr.26561] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 10.8] [Reference Citation Analysis]
204 Li PD, Chen P, Peng X, Ma C, Zhang WJ, Dai XF. HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition. Aging (Albany NY) 2018;10:115-30. [PMID: 29348394 DOI: 10.18632/aging.101363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
205 Yang L, Xu J, Ou D, Wu W, Zeng Z. Hepatectomy for huge hepatocellular carcinoma: single institute's experience. World J Surg. 2013;37:2189-2196. [PMID: 23665818 DOI: 10.1007/s00268-013-2095-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
206 Osaki A, Suda T, Waguri N, Ishikawa T, Yokoo T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Aoyagi Y. Formula to Predict Platelet Count after Partial Splenic Arterial Embolization in Patients with Hypersplenism. Journal of Vascular and Interventional Radiology 2012;23:900-7. [DOI: 10.1016/j.jvir.2012.03.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
207 Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M;  Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. Ann Surg. 2020;272:145-154. [PMID: 30672806 DOI: 10.1097/sla.0000000000003192] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 16.0] [Reference Citation Analysis]
208 Liu L, Zhang C, Zhao Y, Qi X, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int. 2014;2014:194278. [PMID: 24800212 DOI: 10.1155/2014/194278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
209 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Liver Research 2020;4:199-205. [DOI: 10.1016/j.livres.2020.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
210 Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ohkawa A. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:e529-e535. [PMID: 22284041 DOI: 10.1016/j.ijrobp.2011.05.056] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
211 Tsai WL, Sun WC, Chen WC, Chiang CL, Lin HS, Liang HL, Cheng JS. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e21489. [PMID: 32769883 DOI: 10.1097/MD.0000000000021489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
212 Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 2011;46:359-66. [DOI: 10.1007/s00535-010-0306-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
213 Kim Y, Park J, Kwak H, Kim BH, Lee JH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Kim C. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. Liver Int 2014;34:1278-86. [DOI: 10.1111/liv.12535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
214 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol 2009;15:1843-8. [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
215 Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. World J Hepatol. 2014;6:844-850. [PMID: 25544871 DOI: 10.4254/wjh.v6.i12.844] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
216 Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121-30; quiz 1131. [PMID: 19640737 DOI: 10.1016/j.jvir.2009.05.030] [Cited by in Crossref: 226] [Cited by in F6Publishing: 171] [Article Influence: 18.8] [Reference Citation Analysis]
217 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
218 Hu H, Chen GF, Yuan W, Wang JH, Zhai B. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia 2018;34:1351-8. [PMID: 29720001 DOI: 10.1080/02656736.2018.1462536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
219 Osuga K, Arai Y, Anai H, Takeuchi Y, Aramaki T, Sugihara E, Yamamoto T, Inaba Y, Ganaha F, Seki H. Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401. J Vasc Interv Radiol. 2012;23:1278-1285. [PMID: 22922041 DOI: 10.1016/j.jvir.2012.06.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
220 Peng ZW, Chen MS. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma. Oncology. 2013;84 Suppl 1:40-43. [PMID: 23428857 DOI: 10.1159/000345888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
221 Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9:617-623.e1. [PMID: 21459158 DOI: 10.1016/j.cgh.2011.03.027] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 7.8] [Reference Citation Analysis]
222 Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers (Basel) 2021;13:E160. [PMID: 33466496 DOI: 10.3390/cancers13010160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
223 Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T, Hayashi N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010;52:872-879. [PMID: 20395004 DOI: 10.1016/j.jhep.2009.12.030] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
224 Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-1335. [PMID: 22314428 DOI: 10.1016/j.jhep.2012.01.008] [Cited by in Crossref: 284] [Cited by in F6Publishing: 246] [Article Influence: 31.6] [Reference Citation Analysis]
225 Hirooka M, Ochi H, Koizumi Y, Tokumoto Y, Hiraoka A, Kumagi T, Abe M, Tanaka H, Hiasa Y. Local recurrence of hepatocellular carcinoma in the tumor blood drainage area following radiofrequency ablation. Mol Clin Oncol 2014;2:182-6. [PMID: 24649330 DOI: 10.3892/mco.2013.229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
226 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
227 Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:341-57. [PMID: 26558422 DOI: 10.1586/17474124.2016.1116381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
228 Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39-50. [PMID: 26020028 DOI: 10.1159/000367727] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 13.7] [Reference Citation Analysis]
229 Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol 2017;209:722-32. [PMID: 28705059 DOI: 10.2214/AJR.17.18219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
230 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 114] [Article Influence: 14.0] [Reference Citation Analysis]
231 Bartnik K, Podgórska J, Rosiak G, Korzeniowski K, Giziński J, Sajdek M, Wróblewski T, Zieniewicz K, Nyckowski P, Rowiński O. Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study. J Cancer Res Clin Oncol 2021. [PMID: 33778924 DOI: 10.1007/s00432-021-03603-9] [Reference Citation Analysis]
232 Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, Hayashi N. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008;99:1643-1649. [PMID: 18754878 DOI: 10.1111/j.1349-7006.2008.00859.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
233 Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012;47:577-85. [PMID: 22231575 DOI: 10.1007/s00535-011-0522-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
234 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
235 Yamamoto M, Tatsumi T, Miyagi T, Tsunematsu H, Aketa H, Hosui A, Kanto T, Hiramatsu N, Hayashi N, Takehara T. α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011;165:211-219. [PMID: 21592114 DOI: 10.1111/j.1365-2249.2011.04421.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
236 Biolato M, Miele L, Vero V, Racco S, Di Stasi C, Iezzi R, Zanché A, Pompili M, Rapaccini GL, La Torre G, Gasbarrini A, Grieco A. Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. World J Gastroenterol 2014;20:8158-65. [PMID: 25009388 DOI: 10.3748/wjg.v20.i25.8158] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
237 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031-1036. [PMID: 26647219 DOI: 10.1111/jgh.13250] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 27.3] [Reference Citation Analysis]
238 Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475-4483. [PMID: 21437884 DOI: 10.1002/cncr.25960] [Cited by in Crossref: 228] [Cited by in F6Publishing: 176] [Article Influence: 22.8] [Reference Citation Analysis]
239 Jiang TA, Deng Z, Tian G, Zhao QY, Wang WL. Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients. Sci Rep 2016;6:36098. [PMID: 27958384 DOI: 10.1038/srep36098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
240 Kim BK, Kim KA, Kim M, Park JY, Kim DY, Ahn SH, Han K, Kim SU, Park M. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Digestive and Liver Disease 2015;47:682-8. [DOI: 10.1016/j.dld.2015.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
241 Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, Yu HC, Tsay FW, Wang HM, Tsai HC, Cheng JS. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One 2014;9:e92784. [PMID: 24824520 DOI: 10.1371/journal.pone.0092784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
242 Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7:418-428. [PMID: 30652086 DOI: 10.21037/hbsn.2018.09.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
243 Tsai Y, Hsu C, Huang Y, Su C, Lin H, Lee R, Chiang J, Huo T, Lee S. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84. [DOI: 10.1007/s12072-011-9276-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
244 Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, Kim YJ, Lee HS, Jae HJ, Park JH. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol. 2013;24:274-283. [PMID: 23369561 DOI: 10.1016/j.jvir.2012.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
245 Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, Shoda J, Sakurai H, Tsuboi K, Tokuuye K. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer. 2009;115:5499-5506. [PMID: 19645024 DOI: 10.1002/cncr.24619] [Cited by in Crossref: 89] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
246 Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2016;39:359-366. [PMID: 26711804 DOI: 10.1007/s00270-015-1237-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
247 Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World J Gastroenterol. 2015;21:3035-3040. [PMID: 25780303 DOI: 10.3748/wjg.v21.i10.3035] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
248 Yu Y, Lang Q, Chen Z, Li B, Yu C, Zhu D, Zhai X, Ling C. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer. 2009;115:5132-5138. [PMID: 19672999 DOI: 10.1002/cncr.24567] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
249 Wang Y, Zheng C, Liang B, Zhao H, Qian J, Liang H, Feng G. Hepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemoembolization in a standardized rabbit model. J Vasc Interv Radiol 2011;22:1606-12. [PMID: 21959058 DOI: 10.1016/j.jvir.2011.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
250 Cohen MJ, Levy I, Barak O, Bloom AI, Fernández-Ruiz M, Di Maio M, Perrone F, Poon RT, Shouval D, Yau T. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014;34:1109-1117. [PMID: 24512125 DOI: 10.1111/liv.12486] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
251 Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2007;37:676-691. [PMID: 17617112 DOI: 10.1111/j.1872-034x.2007.00119.x] [Cited by in Crossref: 282] [Cited by in F6Publishing: 107] [Article Influence: 28.2] [Reference Citation Analysis]
252 Park SS, Lee DM, Lim JH, Lee D, Park SJ, Kim HM, Sohn S, Yoon G, Eom YW, Jeong S, Choi EK, Choi KS. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis. Carcinogenesis 2018;39:458-70. [DOI: 10.1093/carcin/bgy003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
253 Vasuri F, Malvi D, Rosini F, Baldin P, Fiorentino M, Paccapelo A, Ercolani G, Pinna AD, Golfieri R, Morselli-Labate AM, Grigioni WF, D'Errico-Grigioni A. Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol 2014;20:13538-45. [PMID: 25309084 DOI: 10.3748/wjg.v20.i37.13538] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
254 Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, Takayama H, Abe T, Sato K, Kakizaki S. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatol Res. 2018;48:165-175. [PMID: 28500686 DOI: 10.1111/hepr.12912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
255 Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, Lee JH, Kim SU, Kim DY, Ahn SH, Hwang SG, Han KH, Rim KS, Park JY. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel) 2019;11:E509. [PMID: 30974843 DOI: 10.3390/cancers11040509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
256 Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186-94. [PMID: 20879017 DOI: 10.1002/lt.22129] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
257 Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol. 2012;57:1258-1267. [PMID: 22871502 DOI: 10.1016/j.jhep.2012.07.025] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
258 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 222] [Article Influence: 83.6] [Reference Citation Analysis]
259 Ukawa S, Okada E, Nakamura K, Hirata M, Nagai A, Matsuda K, Yamagata Z, Kamatani Y, Ninomiya T, Kiyohara Y, Muto K, Kubo M, Nakamura Y, Tamakoshi A; BioBank Japan Cooperative Hospital Group. Characteristics of patients with liver cancer in the BioBank Japan project. J Epidemiol 2017;27:S43-8. [PMID: 28214185 DOI: 10.1016/j.je.2016.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
260 Zalinski S, Scatton O, Randone B, Vignaux O, Dousset B. Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization. World J Gastroenterol. 2008;14:6869-6872. [PMID: 19058317 DOI: 10.3748/wjg.14.6869] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
261 Zhang YF, Wei W, Guo ZX, Wang JH, Shi M, Guo RP. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Jpn J Clin Oncol. 2015;45:837-843. [PMID: 26079139 DOI: 10.1093/jjco/hyv089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
262 Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M, Wang W, Kubota Y, Goto T, Komiyama Y, Higuchi M, Takaura K, Hayashi T, Takada H, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Himeno Y, Izumi N. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442-50. [PMID: 29278654 DOI: 10.1111/hepr.13048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
263 Yang ZW, He W, Zheng Y, Zou RH, Liu WW, Zhang YP, Wang CW, Wang YJ, Yuan YC, Li BK, Yuan YF. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9:4000-8. [PMID: 30410605 DOI: 10.7150/jca.24250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
265 Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, Shi HY, Ker CG, Chiu HC. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009;99:343-50. [PMID: 19226530 DOI: 10.1002/jso.21248] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
266 Zhang Y, Hui F, Yang Y, Chu H, Qin X, Zhao M, Zhao Q. Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis. Oncotarget 2017;8:107258-72. [PMID: 29291026 DOI: 10.18632/oncotarget.20921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
267 Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22:160-167. [PMID: 27044767 DOI: 10.3350/cmh.2016.22.1.160] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
268 Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116:3638-3644. [PMID: 20564097 DOI: 10.1002/cncr.25142] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
269 Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, Fujii T, Nakayama G, Yamada S, Tanaka C, Kobayashi D, Kodera Y. Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther 2013;6:1417-24. [PMID: 24143113 DOI: 10.2147/OTT.S51913] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
270 Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015;2:399-408. [PMID: 26998220 DOI: 10.2217/hep.15.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
271 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
272 Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW. [Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol. 2009;15:474-485. [PMID: 20037266 DOI: 10.3350/kjhep.2009.15.4.474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
273 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
274 Jia W, Feng K, Fan P, Fan G, Yang S, Zhang T, Wei Q, Qian L. Post-TACE Combination Therapy of Heparin and Octreotide Results in Decreased Tumor Metastasis in Extrahepatic Tumorigenesis. Cell Biochem Biophys 2012;62:35-40. [DOI: 10.1007/s12013-011-9255-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
275 Park YS, Kim JH, Kim KW, Lee IS, Yoon HK, Ko GY, Sung KB. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol. 2009;64:779-785. [PMID: 19589416 DOI: 10.1016/j.crad.2009.02.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
276 Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, Levi I, Shibolet O. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19:2521-2528. [PMID: 23674854 DOI: 10.3748/wjg.v19.i16.2521] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
277 Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, Notsumata K, Toya D, Tanaka N. Chemoembolization for the treatment of large hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:1226-1234. [PMID: 20598571 DOI: 10.1016/j.jvir.2010.04.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
278 Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Shimizu Y, Shiraishi A, Yamago H, Tanihira T, Miyata H, Ninomiya T, Kawasaki H, Ishimaru Y, Sogabe I, Inoue T, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K. Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: Impact of FDG PET/CT. Liver Int. 2013;33:1085-1091. [PMID: 23601196 DOI: 10.1111/liv.12161] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
279 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 14.2] [Reference Citation Analysis]
280 Shrimal A, Prasanth M, Kulkarni AV. Interventional radiological treatment of hepatocellular carcinoma: an update. Indian J Surg 2012;74:91-9. [PMID: 23372313 DOI: 10.1007/s12262-011-0377-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
281 Lee I, Huo T, Huang Y, Chao Y, Li C, Lee P, Chiang J, Su C, Lan K, Yang C, Wu J, Lin H, Lee S. Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatol Int 2012;6:753-62. [DOI: 10.1007/s12072-011-9322-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
282 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
283 Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol. 2012;33:2401-2409. [PMID: 22965881 DOI: 10.1007/s13277-012-0504-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
284 Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. Journal of Hepatology 2012;56:886-92. [DOI: 10.1016/j.jhep.2011.10.021] [Cited by in Crossref: 112] [Cited by in F6Publishing: 96] [Article Influence: 12.4] [Reference Citation Analysis]
285 Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, Su L, Tian JJ, Gai ZT. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648. [PMID: 22970277 DOI: 10.1371/journal.pone.0044648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
286 Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, Chen Z, Chen Z, Luo Z, Wang X, Kong J, Li G, Wang H, Leo HL, Yu H, Xi L, Guo Q. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials 2020;240:119855. [DOI: 10.1016/j.biomaterials.2020.119855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
287 Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, Chen W, Bai J, Wang Z. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19:437-445. [PMID: 18795303 DOI: 10.1007/s00330-008-1137-0] [Cited by in Crossref: 138] [Cited by in F6Publishing: 94] [Article Influence: 10.6] [Reference Citation Analysis]
288 Sangro B, D'avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:1057-73. [DOI: 10.1517/14656566.2011.545346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
289 Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in HCC Patients Treated with Transarterial Chemoembolization. HPB Surg. 2016;2016:6120143. [PMID: 27143815 DOI: 10.1155/2016/6120143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
290 Min YW, Kim J, Kim S, Sung YK, Lee JH, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW. Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 2013;33:197-202. [PMID: 23295052 DOI: 10.1111/liv.12023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
291 Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 6.6] [Reference Citation Analysis]
292 Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, Lu SN. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:358-363. [PMID: 25088668 DOI: 10.1111/jgh.12686] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
293 Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. Eur J Gastroenterol Hepatol 2018;30:44-53. [PMID: 29076939 DOI: 10.1097/MEG.0000000000001005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
294 Kan RW, Tsang SH, Poon RT, Cheung TT. Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma. ANZ J Surg. 2012;82:505-509. [PMID: 22747591 DOI: 10.1111/j.1445-2197.2012.06121.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
295 Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther 2007;26:839-46. [PMID: 17767468 DOI: 10.1111/j.1365-2036.2007.03424.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
296 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
297 Choi JW, Kim H, Chung JW, Kim JD, Kim GM, Lee IJ, Jae HJ, Park JH. Chemoembolization Via Branches from the Splenic Artery in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2012;35:90-6. [DOI: 10.1007/s00270-011-0109-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
298 Li H, Li S, Geng J, Zhao S, Tan K, Yang Z, Feng D, Liu L. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies. Ann Transl Med 2020;8:540. [PMID: 32411763 DOI: 10.21037/atm.2020.02.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1543-1549. [PMID: 20796153 DOI: 10.1111/j.1440-1746.2010.06303.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
300 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7:1913-1920. [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
301 Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Goo DE, Park SY. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Gut Liver 2017;11:409-16. [PMID: 28208001 DOI: 10.5009/gnl16001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
302 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 13.8] [Reference Citation Analysis]
303 Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, Yoshie Y, Sanada T, Notsumata K, Tanaka N. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res. 2009;39:374-381. [PMID: 19054146 DOI: 10.1111/j.1872-034x.2008.00465.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
304 Liu T, Kan XF, Ma C, Chen LL, Cheng TT, Zou ZW, Li Y, Cao FJ, Zhang WJ, Yao J, Li PD. GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma. Tumour Biol 2017;39:1010428317700410. [PMID: 28635398 DOI: 10.1177/1010428317700410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
305 Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011;17:556-566. [PMID: 21506244 DOI: 10.1002/lt.22273] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
306 Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology 2016;27:1279-87. [DOI: 10.1016/j.jvir.2016.01.135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
307 Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2008;19:862-9. [DOI: 10.1016/j.jvir.2008.02.013] [Cited by in Crossref: 110] [Cited by in F6Publishing: 87] [Article Influence: 8.5] [Reference Citation Analysis]
308 Chu HH, Kim JH, Yoon HK, Ko HK, Gwon DI, Kim PN, Sung KB, Ko GY, Kim SY, Park SH. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. J Vasc Interv Radiol. 2019;30:1533-1543. [PMID: 31471190 DOI: 10.1016/j.jvir.2019.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
309 Chou C, Huang Y, Lee C, Lee K, Chen Y, Chen R. Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma in Interlobar Watershed Zone of Liver: Comparison of Unilateral and Bilateral Chemoembolization. Journal of Vascular and Interventional Radiology 2012;23:1036-42. [DOI: 10.1016/j.jvir.2012.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
310 Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, Gupta AK, Acharya SK. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging. 2011;21:113-120. [PMID: 21799594 DOI: 10.4103/0971-3026.82294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
311 Zhang Y, Qu S, Yi W, Zhai J, Zhang X, Wei L, Lau WY, Wu M, Shen F, Fan H, Wu D. A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819844488. [PMID: 31204599 DOI: 10.1177/1533033819844488] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
312 Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:15-46. [PMID: 31655492 DOI: 10.1111/hepr.13438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 51.0] [Reference Citation Analysis]
313 Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, Orito N, Notsumata K, Watanabe H, Toya D, Tanaka N, Matsui O. Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:1168-1179. [PMID: 20058008 DOI: 10.1007/s00270-009-9781-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
314 Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
315 Choi SH, Choi GH, Kim SU, Park JY, Joo DJ, Ju MK, Kim MS, Choi JS, Han KH, Kim SI. Role of surgical resection for multiple hepatocellular carcinomas. World J Gastroenterol. 2013;19:366-374. [PMID: 23372359 DOI: 10.3748/wjg.v19.i3.366] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
316 Vogl TJ, Naguib NN, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol. 2010;20:173-180. [PMID: 19657653 DOI: 10.1007/s00330-009-1525-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
317 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
318 Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:747-59. [PMID: 32953158 DOI: 10.21037/jgo-20-59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
319 Wagle P, Narkhede R, Desai G, Pande P, Kulkarni DR, Varty P. SURGICAL MANAGEMENT OF LARGE HEPATOCELLULAR CARCINOMA: THE FIRST SINGLE-CENTER STUDY FROM WESTERN INDIA. Arq Bras Cir Dig 2020;33:e1505. [PMID: 33237158 DOI: 10.1590/0102-672020190001e1505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
320 Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One. 2014;9:e112184. [PMID: 25372403 DOI: 10.1371/journal.pone.0112184] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
321 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
322 Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterol J 2015;3:284-93. [PMID: 26279838 DOI: 10.1177/2050640615575971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
323 Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413-420. [PMID: 20839057 DOI: 10.1245/s10434-010-1321-8] [Cited by in Crossref: 205] [Cited by in F6Publishing: 194] [Article Influence: 18.6] [Reference Citation Analysis]
324 Yinglu F, Changquan L, Xiaofeng Z, Bai L, Dezeng Z, Zhe C. A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization. J Altern Complement Med 2009;15:175-81. [PMID: 19216654 DOI: 10.1089/acm.2008.0093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
325 Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008;8:1643-1650. [PMID: 18925855 DOI: 10.1586/14737140.8.10.1643] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
326 Moore A, Cohen-Naftaly M, Benjaminov O, Braun M, Issachar A, Mor E, Tovar A, Sarfaty M, Gordon N, Stemmer SM. Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer 2016;7:883-9. [PMID: 27313777 DOI: 10.7150/jca.14721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
327 Liang L, Chen TH, Li C, Xing H, Han J, Wang MD, Zhang H, Lau WY, Wu MC, Shen F, Yang T. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20:1119-1129. [PMID: 30056066 DOI: 10.1016/j.hpb.2018.06.1804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
328 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1562] [Article Influence: 321.3] [Reference Citation Analysis]
329 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 93] [Article Influence: 9.8] [Reference Citation Analysis]
330 Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, Liu CJ, Lin CL, Yu MW. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012;131:2612-2621. [PMID: 22362517 DOI: 10.1002/ijc.27508] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
331 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs Real World Outcomes 2020;7:141-9. [PMID: 32048238 DOI: 10.1007/s40801-020-00179-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
332 Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther. 2008;19:915-926. [PMID: 18759560 DOI: 10.1089/hum.2007.153] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
333 Metussin A, Patanwala I, Cross TJ. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2015;62:747-748. [PMID: 25450210 DOI: 10.1016/j.jhep.2014.08.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
334 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
335 Wang P, Sheng L, Wang G, Wang H, Huang X, Yan X, Yang X, Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol 2014;2:203-6. [PMID: 24649333 DOI: 10.3892/mco.2014.239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
336 Miyayama S, Yamashiro M, Hashimoto M, Hashimoto N, Ikuno M, Okumura K, Yoshida M, Matsui O. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol 2013;24:501-8. [PMID: 23452552 DOI: 10.1016/j.jvir.2012.12.022] [Cited by in Crossref: 84] [Cited by in F6Publishing: 53] [Article Influence: 10.5] [Reference Citation Analysis]
337 Lewis AR, Padula CA, McKinney JM, Toskich BB. Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions. Semin Intervent Radiol 2019;36:303-9. [PMID: 31680721 DOI: 10.1055/s-0039-1697641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Tu J, Jia Z, Ying X, Zhang D, Li S, Tian F, Jiang G. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5606. [PMID: 27930585 DOI: 10.1097/MD.0000000000005606] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
339 Massarweh NN, Davila JA, El-Serag HB, Duan Z, Temple S, May S, Sada YH, Anaya DA. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res 2016;200:552-9. [PMID: 26507276 DOI: 10.1016/j.jss.2015.09.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
340 Sotiropoulos GC, Drühe N, Sgourakis G, Molmenti EP, Beckebaum S, Baba HA, Antoch G, Hilgard P, Radtke A, Saner FH, Nadalin S, Paul A, Malagó M, Broelsch CE, Lang H. Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach? Dig Dis Sci 2009;54:2264-73. [DOI: 10.1007/s10620-008-0604-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
341 Tang C, Shen J, Feng W, Bao Y, Dong X, Dai Y, Zheng Y, Zhang J. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016;95:e3754. [PMID: 27196501 DOI: 10.1097/MD.0000000000003754] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
342 Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199-210. [PMID: 24077865 DOI: 10.1007/s00432-013-1528-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
343 Gomes AS, Rosove MH, Rosen PJ, Amado RG, Sayre JW, Monteleone PA, Busuttil RW. Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. AJR Am J Roentgenol. 2009;193:1665-1671. [PMID: 19933662 DOI: 10.2214/ajr.08.1806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
344 Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis 2011;43:905-11. [PMID: 21802381 DOI: 10.1016/j.dld.2011.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
345 Gnutzmann D, Kortes N, Sumkauskaite M, Schmitz A, Weiss KH, Radeleff B. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. Minim Invasive Ther Allied Technol 2018;27:69-80. [PMID: 29381102 DOI: 10.1080/13645706.2018.1432489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
346 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol. 2013;5:302-310. [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
347 Li L, Gou C, Li J, Achakzai R, Li X. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Hepatobiliary & Pancreatic Diseases International 2016;15:152-7. [DOI: 10.1016/s1499-3872(16)60070-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
348 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N;  Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938-943. [PMID: 27266618 DOI: 10.1016/j.jhep.2016.05.044] [Cited by in Crossref: 156] [Cited by in F6Publishing: 139] [Article Influence: 31.2] [Reference Citation Analysis]
349 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
350 Liu Z, Chen M, Xie LK, Liu T, Zou ZW, Li Y, Chen P, Peng X, Ma C, Zhang WJ, Li PD. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling. Aging (Albany NY) 2018;10:2570-84. [PMID: 30312171 DOI: 10.18632/aging.101571] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
351 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
352 Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, Ueno H, Okusaka T, Arai Y, Takayasu K. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337-2347. [PMID: 17503155 DOI: 10.1245/s10434-007-9415-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
353 Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan: 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 2016;46:372-90. [DOI: 10.1111/hepr.12697] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 17.0] [Reference Citation Analysis]
354 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2012;18:1379-1384. [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
355 Nishi M, Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion. Hepatol Res 2018;48:329-32. [PMID: 29098752 DOI: 10.1111/hepr.12995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
356 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Takikawa Y, Suzuki K. Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2013;19:2242-2248. [PMID: 23599651 DOI: 10.3748/wjg.v19.i14.2242] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
357 Zhu H, Zhou K, Zhang L, Jin C, Peng S, Yang W, Li K, Su H, Chen W, Bai J, Wu F, Wang Z. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. European Journal of Radiology 2009;72:160-6. [DOI: 10.1016/j.ejrad.2008.07.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
358 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012;18:1933-1939. [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
359 Lu L, Zeng J, Wen Z, Tang C, Xu N. Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults. Cochrane Database Syst Rev. 2019;2:CD012244. [PMID: 30776082 DOI: 10.1002/14651858.cd012244.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
360 Tsoulfas G, Mekras A, Agorastou P, Kiskinis D. Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg. 2012;82:510-517. [PMID: 22548726 DOI: 10.1111/j.1445-2197.2012.06079.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
361 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3227] [Article Influence: 404.7] [Reference Citation Analysis]
362 Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017;116:448-54. [PMID: 28125820 DOI: 10.1038/bjc.2016.423] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
363 Hernandez JM, Elahi A, Clark CW, Wang J, Humphries LA, Centeno B, Bloom G, Fuchs BC, Yeatman T, Shibata D. miR-675 Mediates Downregulation of Twist1 and Rb in AFP-Secreting Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:625-35. [DOI: 10.1245/s10434-013-3106-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
364 Wu J, Hecker JG, Chiamvimonvat N. Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev 2009;61:351-63. [PMID: 19233238 DOI: 10.1016/j.addr.2009.01.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
365 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
366 Hiraoka A, Michitaka K, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, Ishimaru Y, Kawasaki H, Koizumi Y, Hirooka M, Yamashita Y, Abe M, Hiasa Y, Matsuura B, Onji M. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010;25:403-407. [PMID: 19929922 DOI: 10.1111/j.1440-1746.2009.06037.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
367 Yan J, Zhang J, Wang M, Yuan K, Bai Y, Wang Y, Xin H, Wang Z, Liu F, Duan F, Fu J. Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm. Asia-Pac J Clin Oncol 2018;14:300-9. [DOI: 10.1111/ajco.12817] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
368 Baba Y, Hayashi S, Ueno K, Nakajo M, Ueno S, Kubo F, Baba Y, Hamanoue M, Hasegawa S, Tsubouchi H, Komorizono Y. Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett 2010;1:905-11. [PMID: 22966404 DOI: 10.3892/ol_00000161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
369 Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, Di Piazza S, Marrone C, Orlando A, Fusco G. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis. 2010;42:515-519. [PMID: 19914153 DOI: 10.1016/j.dld.2009.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
370 Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M; Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-7. [PMID: 20173167 DOI: 10.2214/AJR.09.3308] [Cited by in Crossref: 70] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
371 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
372 Andrisani OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 2011;21:4-9. [PMID: 20851183 DOI: 10.1016/j.semcancer.2010.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
373 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 16.5] [Reference Citation Analysis]
374 Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, Issachar A, Mor E, Sarfaty M, Bragilovski D, Hur RB, Gordon N, Stemmer SM, Allen AM. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017;12:163. [PMID: 29052532 DOI: 10.1186/s13014-017-0899-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
375 Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PMID: 31319016 DOI: 10.1111/liv.14194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
376 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017;9:907-20. [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 16.8] [Reference Citation Analysis]
377 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
378 Wege H, Li J, Ittrich H. Treatment Lines in Hepatocellular Carcinoma. Visc Med 2019;35:266-72. [PMID: 31602390 DOI: 10.1159/000501749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
379 Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S, Terai S. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Manag Res 2018;10:2231-9. [PMID: 30100754 DOI: 10.2147/CMAR.S167417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
380 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 141] [Article Influence: 21.9] [Reference Citation Analysis]
381 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
382 Ismail A, AlDorry A, Shaker M, Elwekeel R, Mokbel K, Zakaria D, Meshaal A, Eldeen FZ, Selim A. Simultaneous injection of autologous mononuclear cells with TACE in HCC patients; preliminary study. J Gastrointest Cancer. 2011;42:11-19. [PMID: 21046282 DOI: 10.1007/s12029-010-9218-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
383 Yang B, You X, Yuan ML, Qin TQ, Duan LJ, He J, Fei ZJ, Zhou X, Zan RY, Liao ZY. Transarterial Ethanol Ablation Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepat Mon. 2016;16:e37584. [PMID: 27799963 DOI: 10.5812/hepatmon.37584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
384 Hamada T, Yano K, Wada T, Imamura N, Hiyoshi M, Kondo K, Nanashima A. Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. World J Surg 2020;44:2770-6. [PMID: 32318792 DOI: 10.1007/s00268-020-05527-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Wang ZX, Liu SL, Sun CH, Wang Q. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: a complementary approach to drug analgesia. World J Gastroenterol 2008;14:931-5. [PMID: 18240352 DOI: 10.3748/wjg.14.931] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
386 Mähringer-Kunz A, Meyer FI, Hahn F, Müller L, Düber C, Pinto Dos Santos D, Galle PR, Weinmann A, Kloeckner R, Schotten S. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterol J 2021;9:590-7. [PMID: 34077613 DOI: 10.1002/ueg2.12098] [Reference Citation Analysis]
387 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
388 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
389 Kanzaki R, Yamada T, Gotoh K, Takahashi H, Murata M, Tomita Y, Yano M, Ohigashi H, Sasaki Y, Ishikawa O. Surgical resection for hepatocellular carcinoma with metastasis to the gallbladder: report of a case. Surg Today 2011;41:285-91. [PMID: 21264771 DOI: 10.1007/s00595-010-4223-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
390 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
391 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
392 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. [PMID: 25120955 DOI: 10.3389/fonc.2014.00198] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 10.7] [Reference Citation Analysis]
393 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
394 Sato N, Kenjo A, Kimura T, Okada R, Ishigame T, Kofunato Y, Shimura T, Abe K, Ohira H, Marubashi S. Prediction of major complications after hepatectomy using liver stiffness values determined by magnetic resonance elastography. Br J Surg 2018;105:1192-9. [PMID: 29683188 DOI: 10.1002/bjs.10831] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
395 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
396 Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-2127. [PMID: 21664811 DOI: 10.1016/j.ejca.2011.05.007] [Cited by in Crossref: 304] [Cited by in F6Publishing: 308] [Article Influence: 30.4] [Reference Citation Analysis]
397 Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, Kodera Y. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res 2013;32:65. [PMID: 24034596 DOI: 10.1186/1756-9966-32-65] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
398 Mizumoto M, Oshiro Y, Okumura T, Fukuda K, Fukumitsu N, Abei M, Ishikawa H, Ohnishi K, Numajiri H, Tsuboi K, Sakurai H. Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy. Radiother Oncol 2014;113:54-9. [PMID: 25248924 DOI: 10.1016/j.radonc.2014.08.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
399 Alexander ES, Mick R, Nadolski GJ, Mondschein JI, Stavropoulos SW, Soulen MC. Combined chemoembolization and thermal ablation for the treatment of metastases to the liver. Abdom Radiol (NY). 2018;43:2859-2867. [PMID: 29500644 DOI: 10.1007/s00261-018-1536-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
400 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
401 Ng KT, Yeung OW, Liu J, Li CX, Liu H, Liu XB, Qi X, Ma YY, Lam YF, Lau MY, Qiu WQ, Shiu HC, Lai MK, Lo CM, Man K. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma. Int J Oncol 2020;57:956-66. [PMID: 32945373 DOI: 10.3892/ijo.2020.5104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
403 Ikushima I, Higashi S, Ishii A, Seguchi K, Iryo Y, Yamashita Y. Ultraselective transcatheter infusion of epirubicin in water-in-oil-in-water emulsion for small hepatocellular carcinoma. Br J Radiol 2012;85:e584-9. [PMID: 22422389 DOI: 10.1259/bjr/16376960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
404 Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguchi T. Repeat treatment for recurrent hepatocellular carcinoma: is it validated? Langenbecks Arch Surg. 2011;396:1093-1100. [PMID: 21847622 DOI: 10.1007/s00423-011-0837-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
405 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda A, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radiol 2012;30:560-6. [PMID: 22644412 DOI: 10.1007/s11604-012-0088-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
406 Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakanuma Y. Clinicopathological significance of 'subtypes with stem-cell feature' in combined hepatocellular-cholangiocarcinoma. Liver Int. 2015;35:1024-1035. [PMID: 24712771 DOI: 10.1111/liv.12563] [Cited by in Crossref: 70] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
407 Kim BK, Shim JH, Kim SU, Park JY, Kim DY, Ahn SH, Kim KM, Lim YS, Han KH, Lee HC. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36:92-99. [PMID: 25950442 DOI: 10.1111/liv.12865] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
408 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
409 Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011;17:1267-75. [PMID: 21455325 DOI: 10.3748/wjg.v17.i10.1267] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
410 Song YG, Shin SW, Cho SK, Choi D, Rhim H, Lee MW, Kim YS, Park KB, Park HS, Choo SW, Do YS, Choo IW, Hyun D. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. Acta Radiol 2015;56:70-7. [PMID: 24518688 DOI: 10.1177/0284185114520857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
411 Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708-718. [PMID: 22187634 DOI: 10.1148/radiol.11110282] [Cited by in Crossref: 186] [Cited by in F6Publishing: 166] [Article Influence: 18.6] [Reference Citation Analysis]
412 Yamasaki T, Saeki I, Harima Y, Zaitsu J, Maeda M, Tanimoto H, Iwamoto T, Hidaka I, Urata Y, Ishikawa T, Takami T, Yamaguchi Y, Uchida K, Terai S, Sakaida I. Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma. J Gastroenterol 2012;47:715-22. [DOI: 10.1007/s00535-012-0537-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
413 Sun JH, Zhang YL, Nie CH, Chen LM, He JD, Wang WL, Zheng SS. Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study. Oncol Lett 2012;3:975-7. [PMID: 22783375 DOI: 10.3892/ol.2012.618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
414 Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24:1123-1134. [PMID: 23562168 DOI: 10.1016/j.jvir.2013.01.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
415 Maiza JC, Vezzosi D, Grunenwald S, Otal P, Guimbaud R, Bennet A, Caron P. Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas. J Endocrinol Invest 2011;34:e253-8. [PMID: 21623151 DOI: 10.3275/7762] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
416 Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, Liu Y, Ye S, Ren Z. The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19 Suppl 3:S375-S384. [PMID: 21681378 DOI: 10.1245/s10434-011-1836-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
417 Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res 2021;51:355-405. [PMID: 33382910 DOI: 10.1111/hepr.13612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
418 Lee M, Chuang VP, Wei C, Cheng T, Cherng M. Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes. European Journal of Radiology 2012;81:1976-9. [DOI: 10.1016/j.ejrad.2011.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
419 Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2013;19:4679-4688. [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
420 Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, Tanaka K. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol 2010;21:1716-24. [PMID: 20884228 DOI: 10.1016/j.jvir.2010.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
421 Zhang ZF, Luo YJ, Lu Q, Dai SX, Sha WH. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? World J Clin Cases 2018;6:259-73. [PMID: 30211206 DOI: 10.12998/wjcc.v6.i9.259] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
422 Seo DD, Lee HC, Jang MK, Min HJ, Kim KM, Lim YS, Chung Y, Lee YS, Suh DJ, Ko G, Lee Y, Lee S. Preoperative Portal Vein Embolization and Surgical Resection in Patients with Hepatocellular Carcinoma and Small Future Liver Remnant Volume: Comparison with Transarterial Chemoembolization. Ann Surg Oncol 2007;14:3501-9. [DOI: 10.1245/s10434-007-9553-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
423 Kawashima M, Kohno R, Nakachi K, Nishio T, Mitsunaga S, Ikeda M, Konishi M, Takahashi S, Gotohda N, Arahira S. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:1479-1486. [PMID: 20605350 DOI: 10.1016/j.ijrobp.2009.12.048] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
424 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol. 2012;53:545-550. [PMID: 22547388 DOI: 10.1258/ar.2012.110476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
425 Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247] [Cited by in Crossref: 164] [Cited by in F6Publishing: 132] [Article Influence: 20.5] [Reference Citation Analysis]
426 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
427 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
428 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
429 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
430 Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM. [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol 2007;13:530-42. [PMID: 18159151 DOI: 10.3350/kjhep.2007.13.4.530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
431 Liao X, Bu Y, Jiang S, Chang F, Jia F, Xiao X, Song G, Zhang M, Ning P, Jia Q. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma. Hepatol Int 2019;13:440-53. [PMID: 31250351 DOI: 10.1007/s12072-019-09960-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
432 Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, Matsui O. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol. 2009;32:255-264. [PMID: 19067043 DOI: 10.1007/s00270-008-9468-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
433 Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, Bilbao JI, Arbizu J, Benito A, Alegre F, D'Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;77:1441-8. [PMID: 20056355 DOI: 10.1016/j.ijrobp.2009.07.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
434 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
435 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 230] [Article Influence: 35.3] [Reference Citation Analysis]
436 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
437 Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH, Song HY. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113:1614-1622. [PMID: 18704990 DOI: 10.1002/cncr.23787] [Cited by in Crossref: 84] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
438 Miyayama S, Matsui O. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome. J Vasc Interv Radiol. 2016;27:1269-1278. [PMID: 27345337 DOI: 10.1016/j.jvir.2016.04.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
439 Nam K, Stanczak M, Lyshchik A, Machado P, Kono Y, Forsberg F, Shaw CM, Eisenbrey JR. Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed Phys Eng Express 2018;4:035039. [PMID: 29887989 DOI: 10.1088/2057-1976/aabb14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
440 Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatology Research 2009;39:432-8. [DOI: 10.1111/j.1872-034x.2008.00477.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
441 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
442 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
443 Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016;26:3492-3499. [PMID: 26801163 DOI: 10.1007/s00330-016-4207-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
444 Bester L, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature: Embolisation therapies in liver cancer. Journal of Medical Imaging and Radiation Oncology 2014;58:341-52. [DOI: 10.1111/1754-9485.12163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
445 Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata T. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:544-554. [PMID: 21739345 DOI: 10.1007/s00270-011-0224-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
446 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 2007;13:2952-5. [PMID: 17589945 DOI: 10.3748/wjg.v13.i21.2952] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
447 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
448 Lin M, Loffroy R, Noordhoek N, Taguchi K, Radaelli A, Blijd J, Balguid A, Geschwind JF. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minim Invasive Ther Allied Technol 2011;20:276-81. [PMID: 21082901 DOI: 10.3109/13645706.2010.536243] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
449 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
450 Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, Chen M. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19:844-852. [PMID: 28070766 DOI: 10.1007/s12094-016-1611-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
451 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 8.2] [Reference Citation Analysis]
452 Yau T, Yao TJ, Chan P, Epstein RJ, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer. 2009;115:5507-5515. [PMID: 19701904 DOI: 10.1002/cncr.24636] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
453 Cai S, Bagby TR, Forrest ML. Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies. Ther Deliv 2011;2:1467-84. [PMID: 22229080 DOI: 10.4155/tde.11.112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
454 Watanabe M, Shibuya A, Minamino T, Murano J, Matsunaga K, Fujii K, Ogasawara G, Irie T, Woodhams R, Koizumi W. Benefits and problems of transarterial therapy in patients with hepatocellular carcinoma and chronic kidney disease. J Vasc Interv Radiol. 2014;25:1947-55; quiz 1955. [PMID: 25306225 DOI: 10.1016/j.jvir.2014.08.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
455 Pandey D, Tan KC. Multimodal Treatment of Huge Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:1550-1550. [DOI: 10.1245/s10434-008-9865-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
456 Yeh ML, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung J Med Sci 2015;31:77-82. [PMID: 25645985 DOI: 10.1016/j.kjms.2014.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
457 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
458 Malbranche C, Boulin M, Guiu B, Pernot C, Cercueil J, Serge Aho L, Musat A, Bedenne L, Hillon P, Guignard M, Fagnoni P. Impact économique de la chimioembolisation avec microsphères chargées dans le traitement du carcinome hépatocellulaire. Bulletin du Cancer 2011;98:671-8. [DOI: 10.1684/bdc.2011.1370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
459 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 10.4] [Reference Citation Analysis]
460 Zhao Y, Fang Z, Luo J, Liu Q, Xu G, Pan H, Wei W, Yan Z. Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent groups in a single center. Exp Ther Med 2015;10:2366-74. [PMID: 26668643 DOI: 10.3892/etm.2015.2822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]